文献速递药物相互作用抗栓抗凝管理

艾尔巴韦/格拉瑞韦治疗丙肝期间华法林敏感性降低

Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

该回顾性队列利用美国退伍军人健康管理局电子病历,纳入43例接受艾尔巴韦/格拉瑞韦联合华法林稳定抗凝的丙肝患者,计算治疗前、治疗12周及治疗结束时的华法林敏感性指数(WSI)。结果显示治疗期间平均WSI从0.53降至0.40(下降25.2%),治疗结束后回升至0.51;治疗期间平均每周华法林剂量从40.3mg增至44.6mg,而平均INR从2.40降至1.96,治疗结束后恢复至2.59。

要点

  • 艾尔巴韦/格拉瑞韦治疗期间华法林敏感性显著下降,需密切监测INR。
  • 治疗期间华法林剂量需增加以维持抗凝强度。
  • 治疗结束后华法林敏感性回升,需警惕抗凝过度。

核心结论

  • 艾尔巴韦/格拉瑞韦加入稳定华法林抗凝治疗时,治疗期间华法林敏感性显著降低,治疗结束后恢复至基线水平。

研究设计与样本

  • 回顾性队列研究,利用美国退伍军人健康管理局电子病历,纳入43例接受艾尔巴韦/格拉瑞韦联合华法林稳定抗凝的丙肝患者,计算治疗前、治疗12周及治疗结束时的华法林敏感性指数(WSI)。

主要发现

  • 治疗期间平均WSI从0.53降至0.40,下降25.2%;治疗结束后回升至0.51。
  • 治疗期间平均每周华法林剂量从40.3mg增至44.6mg,平均INR从2.40降至1.96,治疗结束后恢复至2.59。
  • 治疗前治疗范围内时间百分比为74.1%,治疗期间降至39.8%,治疗结束后12周恢复至64.9%。

临床怎么用

  • 对接受艾尔巴韦/格拉瑞韦治疗的华法林抗凝患者,应加强INR监测并适时调整华法林剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We previously reported an interaction with warfarin anticoagulation when initiating treatment with direct-acting antiviral agents for hepatitis C infection. A decreased warfarin sensitivity led to subtherapeutic anticoagulation. To study this interaction further, we expanded our research to include patients treated with the combination of elbasvir and grazoprevir concurrent with warfarin anticoagulation and investigated changes in warfarin sensitivity during and after treatment. METHODS: Using electronic health records of the Veterans Health Administration, patients starting treatment with elbasvir-grazoprevir for hepatitis C infection concurrent with warfarin anticoagulation were identified. Inclusion required stable warfarin anticoagulation prior to 12 weeks of treatment with elbasvir-grazoprevir. A warfarin sensitivity index (WSI) was calculated at the start of treatment, after 12 weeks after treatment, and at the end of treatment. The primary endpoint was the difference in WSI from pre- to end-treatment. The secondary endpoint was the WSI difference from before treatment to Changes in International Normalized Ratio, warfarin doses, and time in therapeutic range were measured. RESULTS: In the final sample of 43 patients, the mean WSI decreased during treatment from 0.53 to 0.40, or 25.2%. After treatment, the mean WSI rose to 0.51. Although the mean weekly warfarin dose increased from 40.3 to 44.6 mg during treatment, the mean International Normalized Ratio decreased from 2.40 to 1.96, recovering to 2.59 after treatment. The time spent in therapeutic range decreased from 74.1% before treatment to 39.8% during treatment and back to 64.9% 12 weeks posttreatment. CONCLUSION: When elbasvir-grazoprevir was added to stable warfarin anticoagulation, warfarin sensitivity decreased significantly during treatment and returned to baseline after treatment.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. DeCarolis DD, Chen YC, Westanmo AD, et al. Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. Am J Health Syst Pharm. 2019. PMID: 31418789. doi:10.1093/ajhp/zxz127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。